A sensitive, simple, and accurate high-performance liquid chromatographic (HPLC) method has been developed for the determination of tepoxalin, its major metabolite RWJ-20142 and the internal standard RWJ-20294 (Schering-Plough Co.) in horse plasma. The plasma samples (0.5 mL) were directly extracted with acetonitrile 0.9 mL; after high speed centrifugation to precipitate proteins 50 μL were injected into a HPLC. Separation was performed on a Gemini C18 column (250 mm × 4.6 mm i.d., 5 μm particles) with mobile phase A consisting of 0.01 M 1-octane-sulfonic acid in 0.01 M acetic acid aqueous solution and mobile phase B consisting of tetrahydrofuran, using an isocratic elution at 50% and 50% at 1.0 mL/min flow rate. Detection and quantitation were performed by fluorimetric detection at λex = 290 nm and λem = 440 nm. Detection and quantitation limits for tepoxalin and RWJ-20142 were 30 and 50 ng/mL, and 10 and 30 ng/mL, respectively. Recovery values for tepoxalin and RWJ-20142 were near 100%. The linear concentration range for tepoxalin and RWJ 20142 were 50-5000 and 30-5000 ng/mL, respectively. The validated reversed-phase HPLC-fluorescence detection method was used for determination of preliminary pharmacokinetic data of the drug in horse plasma.

Validation of an HPLC-FL method for the determination of tepoxalin and its major metabolite in horse plasma

GIORGI, MARIO;SGORBINI, MICAELA;CORAZZA, MICHELE
2011-01-01

Abstract

A sensitive, simple, and accurate high-performance liquid chromatographic (HPLC) method has been developed for the determination of tepoxalin, its major metabolite RWJ-20142 and the internal standard RWJ-20294 (Schering-Plough Co.) in horse plasma. The plasma samples (0.5 mL) were directly extracted with acetonitrile 0.9 mL; after high speed centrifugation to precipitate proteins 50 μL were injected into a HPLC. Separation was performed on a Gemini C18 column (250 mm × 4.6 mm i.d., 5 μm particles) with mobile phase A consisting of 0.01 M 1-octane-sulfonic acid in 0.01 M acetic acid aqueous solution and mobile phase B consisting of tetrahydrofuran, using an isocratic elution at 50% and 50% at 1.0 mL/min flow rate. Detection and quantitation were performed by fluorimetric detection at λex = 290 nm and λem = 440 nm. Detection and quantitation limits for tepoxalin and RWJ-20142 were 30 and 50 ng/mL, and 10 and 30 ng/mL, respectively. Recovery values for tepoxalin and RWJ-20142 were near 100%. The linear concentration range for tepoxalin and RWJ 20142 were 50-5000 and 30-5000 ng/mL, respectively. The validated reversed-phase HPLC-fluorescence detection method was used for determination of preliminary pharmacokinetic data of the drug in horse plasma.
2011
Giorgi, Mario; G., Ye; Sgorbini, Micaela; Corazza, Michele
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11568/206014
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 3
social impact